Biogen is trading lower as investors continue to re-price the company after its agreement to acquire Apellis in a transaction valued at about $5.6 billion in cash, plus a contingent value right tied to future Syfovre sales milestones. The deal materially shifts Biogen’s capital allocation toward M&A and increases balance-sheet complexity, which can pressure the stock even when the strategic logic is viewed as positive. (globenewswire.com)

Under the agreed terms, Biogen will pay $41 per Apellis share in cash and attach a CVR that can pay up to $4 per share if Syfovre reaches specified global net sales thresholds in future years. Biogen said it expects the transaction to close in Q2 2026 and plans to fund it with a combination of cash and borrowings, with a goal to delever by the end of 2027—language that underscores the near-term leverage and integration focus now being debated in the stock. (globenewswire.com)

Even when an acquisition adds marketed products and future revenue, the first market reaction often centers on (1) the cost of capital for an all-cash structure, (2) execution risk around commercial performance for the acquired portfolio, and (3) the chance that anticipated accretion is pushed out in time. In Biogen’s case, investors are weighing the near-term debt/borrowing component and whether Syfovre’s growth trajectory will be strong enough to justify the headline price and CVR structure. (globenewswire.com)

Key next steps include any additional details on financing, updated leverage targets, and integration milestones as the companies work toward a Q2 2026 closing. Traders will also monitor commentary around Syfovre commercial momentum and how quickly Biogen can translate the acquired revenue base into EPS accretion, which the company has framed as building from 2027. (globenewswire.com)